2024 SABCS Meeting Magazine - 9

DECEMBER 10 (ALL TIMES ARE IN CENTRAL STANDARD TIME)
2:30 - 4:00 p.m.
Career Development: Patient
Driven Protocol Development
ROOM 221 ABC
Moderators: Saranya Chumsri,
Mayo Clinic Comprehensive Cancer
Center, Jacksonville, Florida,
and Brenda Ernst, Mayo Clinic
Comprehensive Cancer Center,
Phoenix, Arizona
* Importance of Partnerships
in Clinical Research
Edith Perez, Mayo Clinic,
Kenwood, California
* Designing Patient-centric
Clinical Trials
Tatiana Prowell, FDA, Silver
Spring, Maryland
* Novel Statistical Designs:
Putting Patients First
Amylou Dueck, Mayo Clinic
Cancer Center, Scottsdale,
Arizona
4:00 - 5:45 p.m.
Educational Session 1: Mind
the Gap - Breast Cancer in
the Young
STARS AT NIGHT 1-2
Moderator: Matteo Lambertini,
University of Genova - IRCCS
Ospedale Policlinico San Martino,
Genoa, Italy
Patient Advocate: Na'Diah Smith,
Dallas, Texas
* Biology of Breast Cancer in
Young Women
Camila Dos Santos, Cold
Spring Harbor Laboratory,
Cold Spring Harbor, New York
* Ovarian Suppression - Who,
When, Why, and for How
Long
Prudence Francis, Peter
MacCallum Cancer Centre,
Melbourne, Australia
* Survivorship
Jennifer Sheng, Johns
Hopkins University, Baltimore,
Maryland
* Panel Discussion
Educational Session 2: Liquid
Biopsy: MRD, CT DNA, and
Monitoring Response to
Treatment
HEMISFAIR BALLROOM 1-2
Moderator: Adrian Lee, University
of Pittsburgh, Pittsburgh,
Pennsylvania
Patient Advocate: Ellen
Landsberger, New York City
* Review of Current
Technologies
Heather Parsons, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* Early Detection and Molecular
Recurrent Disease
Ben Park, Vanderbilt
University Medical Center,
Nashville, Tennessee
* Utility in the Metastatic
Setting
David Cescon, UHN Princess
Margaret Cancer Centre,
Toronto, Canada
* Panel Discussion
Educational Session 3: Tumor
Heterogeneity and Evolution
HEMISFAIR BALLROOM 3
Moderator: Reuben S. Harris, UT
Health San Antonio, San Antonio,
Texas
* Therapy Induced Evolution
Nicholas Navin, UT MD
Anderson Cancer Center,
Houston, Texas
* Genomic and
Microenvironment
Determinants of Breast
Cancer Progression
Christina Curtis, Stanford
University, Stanford,
California
* Single Cell Genomics in
Triple Negative Breast
Cancer
Ashley Laughney, Weill Cornell
Medicine, New York, New York
* Panel Discussion
Educational Session 4:
Optimizing Early HER2
Positive Breast Cancer
Treatment
STARS AT NIGHT 3-4
Moderator: Javier Cortes,
International Breast Cancer Center,
Barcelona, Spain
December 10-13, 2024 | San Antonio, Texas
Tuesday
Patient Advocate: Thelma Brown,
Birmingham, Alabama
* Neoadjuvant Management
and Adaptive Strategies
Gabe Sonke, Netherlands
Cancer Institute, Amsterdam,
Netherlands
* Treatment of Small Tumors
in Early-Stage Setting
Adrienne Waks, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* Post Neoadjuvant
Management for non pCR
Joyce O'Shaughnessy, Baylor
Charles A. Sammons Cancer
Center, Dallas, Texas
* Panel Discussion
5:45 - 6:15 p.m.
Refreshment and Networking
Break
MAIN LOBBY
6:00 - 7:00 p.m.
Late-Breaking Oral
Presentations
STARS AT NIGHT 1-2
Moderator: Rita Nanda, University
of Chicago Medicine, Chicago,
Illinois
* LB1-01: Long-term effects of
the omission of immediate
surgery in operable breast
cancer, or reduction of
surgical extent: patient-level
meta-analysis of the four
randomised trials among
2,514 women.
Robert Hills, University
of Oxford, Oxford, United
Kingdom
* LB1-02: MARGOT/
TBCRC052: A randomized
phase II trial comparing
neoadjuvant paclitaxel/
margetuximab/pertuzumab
(TMP) vs paclitaxel/
trastuzumab/pertuzumab
(THP) in patients (pts) with
stage II-III HER2+ breast
cancer.
Adrienne Waks, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* LB1-03: Primary results
of the randomised Phase
III trial comparing firstline
ET plus palbociclib
vs standard monochemotherapy
in women
with high risk HER2-/
HR+ metastatic breast
cancer and indication for
chemotherapy - PADMA
study.
Sibylle Loibl, German
Cooperative Group,
Neu-Isenburg, Germany
* LB1-04: Efficacy and safety
of trastuzumab deruxtecan
(T-DXd) vs physician's
choice of chemotherapy
(TPC) by pace of disease
progression on prior
endocrine-based therapy:
additional analysis from
DESTINY-Breast06.
Aditya Bardia, UCLA David
Geffen School of Medicine,
Los Angeles, California
* LB1-05: ROSC (Neo)
adjuvant nab-PAC weekly
vs sb-PAC q2w, followed
by EC q2w, in genomically
or clinically high-risk HR+/
HER- early breast cancer
according to ET-response:
final survival results from
the WSG ADAPT-HR+/
HER2- chemotherapy-trial.
Sherko Kuemmel, German
Medical Institute, Limassol,
Germany
* LB1-06: Primary results
of SOLTI VALENTINE:
neoadjuvant randomized
phase II trial of HER3-DXd
alone or in combination
with letrozole for high-risk
hormone receptor positive
(HR+)/HER2-negative (neg)
early breast cancer (EBC).
Mafalda Oliveira, Vall
d'Hebron University Hospital
and Vall d'Hebron Institute of
Oncology (VHIO), Barcelona,
Spain
* LB1-07: Exploratory
Biomarker Analysis of the
Phase 3 KEYNOTE-522
Study of Neoadjuvant
Pembrolizumab or Placebo
Plus Chemotherapy
Followed by Adjuvant
Pembrolizumab or Placebo
for Early-Stage TNBC.
Joyce O'Shaughnessy, BaylorSammons
Cancer Center,
Dallas, Texas
9
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
